KRONUS VOLTAGE GATED CALCIUM CHANNEL (VGCC) ANTIBODY RIA ASSAY KIT

K111956 · Kronus Market Development Associates, Inc. · PAF · May 30, 2012 · Immunology

Device Facts

Record IDK111956
Device NameKRONUS VOLTAGE GATED CALCIUM CHANNEL (VGCC) ANTIBODY RIA ASSAY KIT
ApplicantKronus Market Development Associates, Inc.
Product CodePAF · Immunology
Decision DateMay 30, 2012
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 866.5660
Device ClassClass 2

Intended Use

The KRONUS Voltage Gated Calcium Channel (VGCC) Antibody RIA Assay Kit is for the semiquantitative determination of antibodies to voltage gated calcium channels in human serum. The VGCC antibody may be present in patients diagnosed with Lambert-Eaton Myasthenic Syndrome (LEMS). The assay result is not to be used alone and is to be used in conjunction with other clinical, electrodiagnostic and laboratory findings.

Device Story

The KRONUS VGCC Antibody RIA Assay Kit is an in vitro diagnostic test used to detect autoantibodies against voltage-gated calcium channels in human serum. The device utilizes a radioimmunoassay (RIA) principle; patient serum is incubated with 125I-labeled VGCC antigen; antibody-antigen complexes are precipitated; radioactivity is measured to determine antibody levels. The assay is performed in a clinical laboratory setting by trained laboratory personnel. Results are provided to clinicians to assist in the diagnosis of Lambert-Eaton Myasthenic Syndrome (LEMS). The output is a semiquantitative measurement of antibody concentration, which must be interpreted alongside clinical symptoms, electrodiagnostic testing, and other laboratory data to support a clinical diagnosis.

Clinical Evidence

No clinical data provided; substantial equivalence is based on analytical performance and comparison to the predicate device.

Technological Characteristics

Radioimmunoassay (RIA) kit; utilizes 125I-labeled VGCC antigen; semiquantitative measurement of autoantibodies in human serum; manual laboratory procedure; requires gamma counter for signal detection.

Indications for Use

Indicated for semiquantitative determination of VGCC antibodies in human serum for patients diagnosed with or suspected of having Lambert-Eaton Myasthenic Syndrome (LEMS). Not for use as a standalone diagnostic; must be used with clinical, electrodiagnostic, and other laboratory findings.

Regulatory Classification

Identification

A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies).

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular, with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the top half of the circle. In the center of the seal is an emblem that resembles a stylized eagle or bird figure. The emblem is composed of flowing lines and curves, giving it a dynamic and modern appearance. ## DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Kronus Market Development Associates, Inc. c/o Ms. Heather Viele Director of Technical Affairs 170 S. Seneca Springs Way, Suite 105 Star, Idaho 83669 HAY 3 0 2012 Re: k111956 Trade/Device Name: Kronus Voltage Gated Calcium Channel (VGCC) Antibody RIA Assay Kit Regulation Number: 21 CFR §866.5660 Regulation Name: Multiple autoantibodies immunological test system Regulatory Class: II Product Codes: PAF Dated: May 2, 2012 Received: May 3, 2012 Dear Ms. Viele: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice {1}------------------------------------------------ ## Page 2 - Ms. Heather Viele requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Reena Philip 0 tr Maria Chan, Ph.D. Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ ## Indications for Use ## 510(k) Number (if known): To be assigned by FDA Device Name: KRONUS Voltage Gated Calcium Channel (VGCC) Antibody RIA Assay Kit Indications for Use Statement: The KRONUS Voltage Gated Calcium Channel (VGCC) Antibody RIA Assay Kit is for the semiquantitative determination of antibodies to voltage gated calcium channels in human serum. The VGCC antibody may be present in patients diagnosed with Lambert-Eaton Myasthenic Syndrome (LEMS). The assay result is not to be used alone and is to be used in conjunction with other clinical, electrodiagnostic and laboratory findings. (Please Do Not Write Below This Line - Continue On another Page If Needed) Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use X (Pursuant to 21 CFR 801.109) OR Over-the-counter Use Kaire Sommitt Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510K k 111956
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%